Somatogen finally completes Phase Ib

Just eight days after filing for a $40 million convertible exchangeable preferred stock offering, Somatogen Inc. announced that it had completed its Phase Ib study of rHb1.1 recombinant hemoglobin in healthy volunteers.

In an industry where investor perceptions of companies can be quixotic, SMTG might have waited